FIELD: medicine.
SUBSTANCE: group of inventions relates to a method of tumour treatment, comprising administering of a nanoparticle complex, where the nanoparticle complex includes costimulatory molecules complexes and antigen/MHC complexes, where each costimulatory complex and each antigen/MHC complex is operably linked to the nanoparticle core. The group of inventions also relates to a method of distribution and/or development of antigen specific anti-tumour T-cells populations in the subject; a method for malignant tumour metastasis inhibition.
EFFECT: effective operating time of T cells that specifically damage the cancer cells, sufficient for significant reduction of tumour size or malignant cells number in vivo.
59 cl, 12 ex, 12, dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2013 |
|
RU2675322C2 |
| NANOPARTICLE COMPOSITIONS FOR LONG-TERM THERAPY | 2016 |
|
RU2773380C2 |
| METHODS AND COMPOSITIONS FOR STABLE IMMUNOTHERAPY | 2014 |
|
RU2696876C2 |
| RECOMBINANT pMHC MOLECULES OF CLASS II | 2017 |
|
RU2777115C2 |
| METHOD FOR TREATING AUTOIMMUNE DISEASE USING BIOCOMPATIBLE BIOABSORBABLE NANOSPHERE | 2011 |
|
RU2635537C2 |
| INDIVIDUALISED VACCINES FOR CANCER | 2012 |
|
RU2670745C9 |
| COATED ONCOLYTIC ADENOVIRUS FOR ANTICANCER VACCINES | 2015 |
|
RU2695375C2 |
| POLYEPITOPE ANTI-TUMOUR VACCINE STRUCTURE CONTAINING EPITOPES OF TUMOR-ASSOCIATED ANTIGENS, PHARMACEUTICAL COMPOSITION AND ITS APPLICATION FOR STIMULATING SPECIFIC ANTI-TUMOR IMMUNE RESPONSE | 2016 |
|
RU2684235C2 |
| METHODS OF PREDICTING THE APPLICABILITY OF DISEASE-SPECIFIC AMINO ACID MODIFICATIONS FOR IMMUNOTHERAPY | 2018 |
|
RU2799341C2 |
| SYSTEM FOR STABLE EXPRESSION OF TUMOR-ASSOCIATED ANTIGENS BASED ON LENTIVIRAL VECTOR | 2018 |
|
RU2725493C2 |
